

№487, 21-fevral, 2022 y.

COVID-19 ga qarshi vaksinalarning  
ishlanmalari bo'yicha

**DAYJEST**

O'zbekiston Respublikasi Innovatsion rivojlanish vazirligi huzuridagi  
Ilmiy-texnik axborot markazi











Toshkent-2022

# Jahonda pandemiya bilan bog'liq vaziyat

2022 y. 20-fevral holatiga ko'ra

Umumiy zararlanganlar soni	-	423 564 026	(+ 1 584 298)
Sog'ayganlar soni	-	348 544 379	(+ 2 041 287)
Vafot etganlar soni	-	5 900 478	(+ 8 124)

## Mamlakatlar bo'yicha bemorlar soni


	AQSh	-	80 072 561	(+ 41 443)
	Hindiston	-	42 822 473	(+ 19 968)
	Braziliya	-	28 167 587	(+ 103 363)
	Fransiya	-	22 227 826	(+ 76 638)
	Buyuk Britaniya	-	18 580 216	(+ 34 377)
	Rossiya	-	15 199 720	(+ 179 147)
	Turkiya	-	13 498 300	(+ 137 722)
	Italiya	-	12 434 130	(+ 80 454)
	Ispaniya	-	12 427 773	(+ 50 534)
	O'zbekiston	-	235 872	(+ 160)

Manba: <https://www.worldometers.info/coronavirus/>




# O'zbekistonda pandemiya bilan bog'liq vaziyat

2022 y. 20-fevral holatiga ko'ra



Yanvar 2022-yil



Fevral 2022-yil



# O'zbekistonda COVID-19 qarshi vaksinatsiya bo'yicha hisobot

2021 y. 19-fevral holatiga ko'ra

Hududlar	Jami emlanganlar soni	Bir kunda emlanganlar soni
Qoraqalpog'iston Respublikasi	2 243 474	3 481
Andijon viloyati	4 405 088	20 940
Buxoro viloyati	2 479 969	8 596
Jizzax viloyati	1 550 960	4 418
Qashqadaryo viloyati	3 575 186	34 432
Navoiy viloyati	1 411 718	6 248
Namangan viloyati	4 183 064	3 370
Samarqand viloyati	5 299 416	8 962
Surxondaryo viloyati	3 554 841	10 032
Sirdaryo viloyati	987 303	4 887
Toshkent viloyati	4 180 205	13 602
Farg'ona viloyati	4 877 190	11 351
Xorazm viloyati	2 665 248	9 435
Toshkent sh.	3 541 828	16 905
<b>Jami</b>	<b>44 955 490</b>	<b>156 659</b>

Manba: SSV matbuot kotibi // <https://t.me/ssvmatbuotkotibi>



# JSST tomonidan baholash jarayonida COVID-19 ga qarshi vaksinlarning holati

2022 y. 18-fevral holatiga ko'ra


№	Ishlab chiqaruvchi	Vaksina nomi	Platforma	Arizalarni qabul qilish	Uchrashuv o'tkazish	Ma'lumotnomani ko'rib chiqish uchun qabul qilish	Baholash holati	Kutilayotgan chiqish sanasi
1	Pfizer	BNT162b2/COMIRNATY	mRNA	+	+	+	Yakunlangan	Tasdiqlangan 31.12.2020
2	AstraZeneca/University of Oxford	AZD1222	Recombinant replication defective chimpanzee adenovirus expressing surface glycoprotein SARS-CoV-2	+	+	+	Yakunlangan	Tasdiqlangan 15.02.2021
3	Janssen	Ad26.COV2.S	Recombinant vector vaccine against adenovirus type 26 (Ad26), incapable of replication, encoding Spike (S) protein (SARS-CoV-2)	+	+	+	Yakunlangan	Tasdiqlangan 12.03.2021
4	SK BIOscience - AstraZeneca/University of Oxford	AZD1222	Recombinant adenoviral vector ChAdOx1 encoding the Spike SARS-CoV-2 protein antigen	+	+	+	Yakunlangan	Tasdiqlangan 16.04.2021
5	Serum institute of India	Covishield	mRNA-based vaccine encapsulated in lipid nanoparticles	+	+	+	Yakunlangan	Tasdiqlangan 16.04.2021
6	Moderna	mRNA-1273	Inactivated, produced in Vero cells	+	+	+	Yakunlangan	Tasdiqlangan 07.05.2021
7	Sinopharm / BIBP	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	Inactivated, produced in Vero cells	+	+	+	Yakunlangan	Tasdiqlangan 01.06.2021
8	Sinovac	SARS-CoV-2 Vaccine (Vero Cell), Inactivated	Protein subunit virus-like particle vaccine	+	+	+	Yakunlangan	Tasdiqlangan 17.12.2021
9	Novavax	NVX-CoV2373, Covovax, Nuvaxovid						

Manba:

Status of COVID-19 Vaccines within WHO EUL // [https://extranet.who.int/pqweb/sites/default/files/documents/Status\\_COVID\\_VAX\\_20Oct2021.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_20Oct2021.pdf)

# Vaksinani tasdiqlagan va undan foydalanilayotgan mamlakatlar soni

2022 y. 18-fevral holatiga ko'ra



Manbalar:

\*Approved or Authorized Vaccines // [https://  
COVID-19 Vaccine Market Dashboard //](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard)

<https://www.unicef.org/supply/covid-19-vaccine-market-dashboard>

\*\*Tracking Coronavirus Vaccinations Around the World //


<https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>



# Mamlakatlar va kontinentlar kesimida COVID-19 ga qarshi emlanganlar soni

2022 y. 18-fevral holatiga ko'ra

№	Davlatlar	Emlanganlar soni		Aholining umumiy sonida emlanganlarning ulushi	
		100 ta kishiga	Jami	Bitta doza bilan emlangan	To'liq emlangan
	<b>Dunyo</b>	<b>136</b>	<b>10 462 335 937</b>	<b>64%</b>	<b>56%</b>
1	BAA	245	23 911 863	99%	96%
2	Brunei	226	979 285	94%	93%
3	Portugaliya	220	22 565 074	94%	90%
4	Kuba	307	34 754 239	93%	87%
5	Chili	251	47 643 248	93%	90%
6	Malta	245	1 233 343	93%	92%
7	Xitoy	219	3 063 391 000	91%	88%
8	Argentina	204	91 462 554	89%	79%
9	Kambodja	206	34 042 032	87%	84%
10	Ispaniya	195	91 716 903	87%	82%




Manba:  
Tracking Coronavirus Vaccinations Around the World // <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>



# COVID-19 ga qarshi vaksinalarning narxi

2022 y. 18-fevral holatiga ko'ra

No	Vaksinaning ishlab chiqaruvchisi	Vaksinalarning narxi (bitta doza uchun)*
1	Pfizer	\$6,75-22,94
2	AstraZeneca/University of Oxford	\$2,19-5
3	Serum institute of India	\$3-13,27
4	Sinopharm	\$144,27 (2 ta doza uchun)
5	Sinovac	\$10,30-29,75
6	Moderna	\$15-37
7	Janssen	\$8,50-10
8	The Gamaleya National Center (Sputnik V)	\$11-19,90



Manba:

\* COVID-19 Vaccine Market Dashboard //

[https://www.unicef.org/supply/covid-19-vaccine-market-](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE)

[dashboard?utm\\_source=facebook&utm\\_medium=organic&utm\\_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE)



# Olimlar koronavirusga qarshi Pfizer kompaniyasining yangi “Paxlovid” preparati samaradorligini ma’lum qilishdi

Biologlar Pfizer tomonidan ishlab chiqarilgan koronavirus infeksiyasiga qarshi yangi Paxlovid (Paxlovid, PF-332) preparatining samaradorligini ma’lum qilishdi. Tadqiqot natijalari Nature Communications jurnalida chop etildi [5].

Paxlovid - bu og‘iz orqali qabul qilinadigan virusga qarshi ikkita nirmatrelvir va ritonavir tabletkalarining kombinatsiyasidir. Ikki tabletkada birgalikda ishlaydi va COVID-19 sababli kasalxonada yotqizilish va o‘limni oldini olishga yordam beradi.



Kompaniyaning ta’kidlashicha, ishlanma odamlar va hayvonlar o‘rtasida COVID-19 ni keltirib chiqaradigan virus tarqalishining oldini olishga yordam beradi. Shuningdek, u Delta va Beta shtammlaridan himoya qilishga qodir. Buni suriyalik hamsterlar ustida o‘tkazilgan in vivo tadqiqot natijalari tasdiqladi [6].

Ta’kidlanishicha, preparatning ta’sir qilish mexanizmi Mpro oqsilini yo‘q qilishga asoslangan. Inson tanasida katta proteinni parchalaydigan proteazlar deb ataladigan moddalar mavjud. Ushbu fermentlarning ingibitorlari proteazlarning harakatni amalga oshirishiga to’sqinlik qiladi. Ushbu bosqichsiz SARS-CoV-2 bo‘linish va ko‘payish hususiyatiga ega emas. Aynan shu protein koronavirus konvertining asosiy fermenti hisoblanadi. Va u ikki baravar oshirilganda, SARS-CoV-2 ning tanada tarqalishi butunlay to‘xtadi va tiklanish sezilarli darajada tezlashdi [7].

Avvalroq Pfizer va BioNTech kompaniyalari Comirnaty vaksinasidan yosh bolalarda foydalanish uchun favqulodda ruxsat olish uchun AQSHda murojaat qilgani haqida xabar berilgan edi. Agar tasdiqlansa, bu olti oylikdan besh yoshgacha bo‘lgan bolalar uchun birinchi koronavirus vaksinasi hisoblanadi.

2021-yil dekabr oyida FDA yengil va o‘rtacha darajadagi COVID-19 ni davolash uchun Paxlovid Emergency Use Authorization (EUA) ni chiqardi. [8] Paxlovid kattalar va og‘ir kasallik xavfi yuqori bo‘lgan bolalarda qo‘llanilishi mumkin. Paxlovidni qabul qilayotgan bolalar kamida 12 yoshda va vazni 40 kg va undan ko‘proq bo‘lishi kerak.

# Kanadada Novavaks COVID-19 vaksinasi tasdiqlandi



Kanada sog'liqni saqlash tizimi Novavax koronavirus vaksinasini tasdiqladi. Nuvaksotsid deb nomlangan preparat mamlakatda tasdiqlangan birinchi oqsilga asoslangan vakcina hisoblanadi. RNK vaksinasi bo'lmagan preparat hali emlashga qaror qilmaganlar uchun ishonchli bo'lishi mumkin [9].

Sog'liqni saqlash vazirligi Novavaks vakinasini 18 va undan katta yoshdagi fuqarolar uchun qo'llashni tasdiqladi. Preparat 21 kunlik interval bilan ikki dozada qo'llaniladi. Vaksinaning klinik sinovlari natijalariga ko'ra, preparat 90% hollarda COVID-19 belgilarini va 100% hollarda og'ir kasallikning oldini oladi. Shuningdek, dastlabki ma'lumotlarga ko'ra vakcina omikron shtammiga qarshi samarali ekanligini ko'rsatdi [10].



Novavax vaksinasi Yevropa, Avstraliya va Singapurda tasdiqlangan. O'tgan yili Kanada hukumati preparatni Monrealda ishlab chiqarish bo'yicha shartnoma imzolagan edi.



Nuvaxocid - Amerikaning Novavax kompaniyasi tomonidan ishlab chiqilgan COVID-19 ga qarshi vakcina. Vakcina tarkibida boshqoq oqsilining laboratoriya versiyasi mavjud. Vakcina yuborilgach, inson tanasida immunitet tizimi oqsilni aniqlaydi va tabiiy himoya qilish uchun unga antitanalar va T hujayralarini ishlab chiqarishni boshlaydi [11].

# Avstraliya bolalar uchun koronavirusga qarshi Moderna vaksinasini tasdiqladi

Avstraliyaning Terapevtik tovarlar boshqarmasi (TGA) tomonidan 6 yoshdan 11 yoshgacha bo'lgan bolalar uchun Amerikaning Moderna kompaniyasining koronavirus vaksinasidan foydalanish tasdiqlandi. Bu haqda 17-fevral kuni regulyator matbuot xizmati xabar berdi [12].

TGA 6 yoshdan 11 yoshgacha bo'lgan bolalarni koronavirusga qarshi emlash uchun Moderna kompaniyasining Spikevax COVID-19 vaksinasini vaqtincha tasdiqladi. Xuddi shu preparat kamroq dozada kattalarni emlash uchun ham qo'llaniladi. Bolalar 28 kunlik interval bilan preparatning ikki dozasi qabul qilishadi.

2021-yil kuzining boshida TGA Spikevax vaksinasini 12 yoshdan 18 yoshgacha bo'lgan o'smirlar uchun qo'llashni tasdiqladi va regulyator tomonidan 2021-yil dekabr oyida vakcina 18 yoshdan oshgan insonlar uchun kuchaytiruvchi vakcina sifatida tasdiqlandi [13, 14] .



## TURKOVAC vaksinasi Turkiyadagi barcha shifoxonalarda qo'llaniladi

Shu haftadan boshlab Turkiyaning COVID-19 ga qarshi mahalliy TURKOVAC vaksinasi Turkiyadagi barcha davlat shifoxonalari mavjud bo'ladi. Bu haqda Turkiya sog'liqni saqlash vazirligi rahbari Fahrettin Koja jurnalistlarga bergan intervyusida ma'lum qildi. Uning ta'kidlashicha, hozirgacha Turkiyadagi shifoxonalarda 800 000 ga yaqin doza TURKOVAC tarqatilgan [15].



Bo'lim boshlig'ining ta'kidlashicha, turkiyalik mutaxassislar mahalliy vaktsinalarni koronavirusning Omikron shtammiga moslashtirish ustida ishlamoqda. "Mahalliy vaktsina hayvonlarda sinovdan o'tkazilmoqda. Hattoki hayvonlarga ikkinchi dozani sinovdan o'tkazishimizga ishonaman. Mart oyiga qadar TURKOVAC vaktsinasini Omicron shtammiga

to'liq moslashtirish rejalashtirmoqda", - dedi vazir.

Shuningdek, bo'lim boshlig'i, hafta oxirida Turkiyada koronavirus bilan kasallanishning eng yuqori cho'qqisiga chiqqanini, biroq ekspertlar prognozlariga ko'ra, keyingi haftadan boshlab o'sish pasayishini ta'kidladi. Hozirga qadar koronavirus bilan kasallangan bemorlarni kasalxonaga yotqizish darajasi 28-30 foizga, reanimatsiya bo'limlarida esa 15 foizga kamaygan», - dedi vazir.



Kojaning aytishicha, vazirlik 23-fevral kuni matbuot anjumani tashkil qiladi, unda Turkiyada koronavirusga qarshi kurash natijalari sarhisob qilinadi va xavfli infeksiya tarqalishining oldini olish bo'yicha hukumatning keyingi qadamlari e'lon qilinadi. Koja, shuningdek, Turkiyadagi shifokorlar koronavirus bilan kasallangan bemorlarni davolash uchun Molnupiravir (Molnupiravir) preparatidan foydalanishni boshlaganini ma'lum qilishdi [16].

Turkovac vaksinasi Erjiyes universiteti tomonidan Turkiya Sog'liqni saqlash vazirligi qoshidagi Xalq salomatligi instituti bilan hamkorlikda ishlab chiqilgan. 22-dekabr kuni vazirlik mamlakatda favqulodda vaziyatlarda foydalanishga ruxsat berdi.

1. Reported Cases and Deaths by Country, Territory, or Conveyance // <https://www.worldometers.info/coronavirus/> (20.02.2022)
2. Approved or Authorized Vaccines // <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html> (18.02.2022)
3. COVID-19 Vaccine Market Dashboard // <https://www.unicef.org/supply/covid-19-vaccine-market-dashboard> (18.02.2022)
4. Tracking Coronavirus Vaccinations Around the World // <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html> (18.02.2022)
5. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern // <https://www.nature.com/articles/s41467-022-28354-0> (20.02.2022)
6. Ученые доказали эффективность нового препарата Pfizer от коронавируса // <https://newsyou.info/2022/02/uchenye-dokazali-effektivnost-novogo-preparata-pfizer-ot-koronavirusa/> (20.02.2022)
7. Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study // <https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate> (20.02.2022)
8. EUA 105 Pfizer Paxlovid LOA // <https://www.fda.gov/media/155049/download> (20.02.2022)
9. Novavax's COVID-19 vaccine approved for Canadians 18 and older // <https://www.cbc.ca/news/health/novavax-health-canada-approval-1.6355106> (20.02.2022)
10. Минздрав Канады одобрил вакцину Novavax от COVID-19 // <https://news.knopka.ca/post/view?id=15936> (20.02.2022)
11. В Канаде одобрена новая вакцина для взрослых // <https://vancouverok.com/news/v-kanade-odobrena-novaya-vakcina-dlya-vzroslyh> (20.02.2022)
12. Novavax's vaccine Nuvoxoid // <https://vaksineeri.ee/en/novavaxs-vaccine-nuvoxoid/> (20.02.2022)
13. Australia the first to approve Moderna vaccine in young children // <https://www1.racgp.org.au/newsgp/clinical/australia-the-first-to-approve-moderna-vaccine-in> (20.02.2022)
14. В Австралии одобрили вакцину от коронавируса для детей компании Moderna // <https://regnum.ru/news/society/3509655.html> (20.02.2022)
15. Вакцину TURKOVAC начнут применять во всех госбольницах Турции // <https://www.aa.com.tr/ru/%D1%82%D1%83%D1%80%D1%86%D0%B8%D1%8F/%D0%B2%D0%B0%D0> (20.02.2022)
16. Вакцину TURKOVAC начнут применять во всех госбольницах Турции // <https://news.day.az/world/1436796.html> (20.02.2022)



O'zbekiston Respublikasi Innovatsion rivojlanish vazirligi huzuridagi  
Ilmiy-texnik axborot markazi

Toshkent-2022